# Preliminary Evaluation of the Safety and Tolerability of SPOT-mRNA01 Subcutaneously Administered in Healthy Subjects

> **NCT06567119** · PHASE1 · NOT_YET_RECRUITING · sponsor: **SIPO Biotechnology Co. Ltd.** · enrollment: 10 (estimated)

## Conditions studied

- Skin Aging

## Interventions

- **BIOLOGICAL:** SPOT-mRNA01
- **OTHER:** Placebo

## Key facts

- **NCT ID:** NCT06567119
- **Lead sponsor:** SIPO Biotechnology Co. Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2027-01-11
- **Primary completion:** 2029-01-12
- **Final completion:** 2029-02-12
- **Target enrollment:** 10 (ESTIMATED)
- **Last updated:** 2026-04-23

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06567119

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06567119, "Preliminary Evaluation of the Safety and Tolerability of SPOT-mRNA01 Subcutaneously Administered in Healthy Subjects". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT06567119. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*